All News

RheumNow Podcast square

Consequences of TNF inhibition (3.18.2022)

Jack Cush, MD

This week we're going to talk about the downside of TNF inhibitors, a few interesting observations in gout, and yes, kids do get COVID. We're also going to preview what's coming in April (hint: it's about PsA). This and more as Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article
pollution,smoke

Environmental Pollutants Ups Autoimmune Disease Risk

Jack Cush, MD

An Italian environmental study shows that air pollution increases the risk of autoimmune diseases, in particular rheumatoid arthritis, connective tissue diseases (CTDs) and inflammatory bowel diseases (IBD).

Read Article
RheumNow Podcast square

RheumNow Live is Coming to Town (3.11.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article
PSA2L.jpg

Psoriatic Arthritis Responds to Tyk2 inhibition with Deucravacitinib

Jack Cush, MD

Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor, was studied in a phase II trial of active psoriatic arthritis (PsA) patients and shown to be effective and safe.

Read Article
pills,combo,push,blister

Combo MTX and Leflunomide in Psoriatic Arthritis

Jack Cush, MD

A recent study has shown that the combination of methotrexate (MTX) plus leflunomide (LEF) yields better disease control in psoriatic arthritis, but may not be as well tolerated as monotherapy with MTX.

Read Article
infusion.biologic.jpg

Drug Survival Differences in RA, PsA, SpA and PsO

Jack Cush, MD

Drug survival may be the best measure of efficacy and safety. A new study of novel therapy durability (survival) in patients with RA, axial spondyloarthritis, PsA, and psoriasis shows that while all these drugs are approved for said conditions, drug survival varies by condition, suggesting an ongoing need for individualized treatment.

Read Article
Study of 338 psoriatic pts assessed carotid total plaque area (TPA) and cardiac troponin I (cTnI) & NT-proBNP. TPA was associated with troponin 1 (β coefficient 0.52) and NT-proBNP (β coefficient 0.24); both p<0.001. https://t.co/NXUBByAD37 https://t.co/ZQMFiqTzDF

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Live is Coming to Town! Have you signed up for RheumNow Live yet? We still have space available. https://t.co/FBCQRu32gO https://t.co/KoGR8An6af https://t.co/qtwPbMzqSO

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: COMPLETE-PsA Trial studied MTX vs MTX + leflunomide in 78 active untreated PsA pts. MTX+LEF was superior to MTX alone at wk 16 (PASDAS 3·1 vs 3·7; p=0·025). Combo group had more N/V (44% v 28%), ^ALT (31% vs 18%). https://t.co/tg5eETiMO4 https://t.co/bC45AAnP3h

Links:

Dr. John Cush RheumNow ( View Tweet)
Psoriatic Arthritis Responds to Tyk2 inhibition with Deucravacitinib Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor, was studied in a phase II trial of active psoriatic arthritis (PsA) patients and shown to be effective and safe. https://t.co/XYK02MRMp6 https://t.co/LgToS5NCaa

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 177 PsA pts, those with dactylitis had more severe disease with signif. greater SJC, CRP, US-detected synovitis and bone erosions in DMARD-naive early PsA. Dactylitis could be useful in early risk stratification. https://t.co/zUoWSEFxaN

Links:

Dr. John Cush RheumNow ( View Tweet)

anti-IL-23 therapy is not effective in Axial Spondyloarthritis. While ustekinumab, guselkumab and risankizumab are approved in psoriasis (& PsA for GUS, RIZ), studies of Ustekinumab and risankizumab failed to show efficacy in axSpA https://t.co/Idlqidy04d https://t.co/su3PI5fSaS

Links:

Dr. John Cush RheumNow ( View Tweet)
Changing to a new biologic or sticking with the old one - a PsA patient chooses QD Clinic is sponsored by https://t.co/4UQlqwujiR (March 19 & 20, 2022 in Las Colinas, Texas) https://t.co/VJ5tuLN6ae https://t.co/OrxVBwNUsx

Links:

Dr. John Cush RheumNow ( View Tweet)
Shared Decision Making in PsA Changing to a new biologic or sticking with the old one - a PsA patient chooses QD Clinic is sponsored by https://t.co/4UQlqwujiR (March 19 & 20, 2022 in Las Colinas, Texas) https://t.co/Hc7ctWtj7A https://t.co/BAApPkxefc

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 155 adult patients (PsA 61/AS 94) looked at labs & CV risk factors; found IL-18 elevated in peripheral PsA more than axial PsA & AS. Elevations were higher in PsA pts w/ ischemic heart disease correlated w/ atherogenic index & TG levels https://t.co/PQ3fBi8Qdo https://t.co/mewrcwhi4o

Links:

Dr. John Cush RheumNow ( View Tweet)
COMPLETE-PsA Trial studied MTX vs MTX + leflunomide in 78 active untreated PsA pts. MTX+LEF was superior to MTX alone at wk 16 (PASDAS 3·1 vs 3·7; p=0·025). Combo group had more N/V (44% v 28%), ^ALT (31% vs 18%). https://t.co/Hc4rNrlQzP https://t.co/UPosZIc4C0

Links:

Dr. John Cush RheumNow ( View Tweet)
Drug Survival Differences in RA, PsA, SpA and PsO https://t.co/aBRhTbVmCM https://t.co/ZDGiKlowoV

Links:

Dr. John Cush RheumNow ( View Tweet)
New Download Available! Autoimmune Disease in the USA https://t.co/KvsgBUY7mL https://t.co/PSTF7ma6G6

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Psoriatic fingernail onycholysis and hyperkeratosis, rather than nail pitting, are significantly & independently assoc w/ PsA. Study of 1985 pts w/psoriasis, 11.5% were Dx w/ PsA. Only onycholysis (OR 2.34) and hyperkeratosis ) were assoc w/ PsA https://t.co/5K8L5WKQXs https://t.co/InDPhLrIUK

Links:

Dr. John Cush RheumNow ( View Tweet)
The worldwide Psoriatic arthritis treatment market is expected to grow from $7.89 billion in 2021 to $8.92 billion in 2022 https://t.co/5gdsUgM08y

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×